Estuary Biotherapeutics emerges with $103 million for kidney disease gene therapies

Estuary Biotherapeutics emerged from stealth on October 16, 2026, with $103 million in funding to advance gene therapies for kidney disease. Led by CEO Wayne Sackett, the biotech is developing two preclinical candidates that aim to address the root cause of autosomal dominant polycystic kidney disease (ADPKD). ADPKD currently has only one FDA-approved treatment, which is limited to slowing disease progression.

Estuary Biotherapeutics $103 million funding

• ▪Wayne Sackett serves as the Chief Executive Officer of Estuary Biotherapeutics
• ▪Estuary Biotherapeutics emerged from stealth on October 16, 2026, with $103 million in funding

ADPKD gene therapy development

• ▪Estuary Biotherapeutics aims to target the root cause of autosomal dominant polycystic kidney disease through its gene therapy pipeline
• ▪Estuary Biotherapeutics is advancing two preclinical gene therapy candidates designed to treat kidney disease

Kidney disease treatment landscape

• ▪Autosomal dominant polycystic kidney disease currently has only one treatment approved by the U.S. Food and Drug Administration
• ▪The sole FDA-approved therapeutic option for autosomal dominant polycystic kidney disease is limited to slowing the progression of the condition